Skip to main content

Alzheimer’s Drug Leqembi Can Be Safely Administered In Memory Clinics, Study Says

Medically reviewed by Carmen Pope, BPharm. Last updated on May 15, 2025.

By Dennis Thompson HealthDay Reporter

THURSDAY, May 15, 2025 — The 2023 approval of the first drug shown to slow the progression of Alzheimer’s disease came with no small amount of concern from skeptics.

Lecanemab (Leqembi) modestly slows Alzheimer’s by helping the body flush out amyloid beta proteins associated with toxic plaques in the brain.

But in clinical trials the drug also came with a risk of brain swelling and bleeding among patients.

Now, a new real-world study has shown that doctors can effectively control these potentially dangerous side effects, researchers reported May 12 in JAMA Neurology.

“Fear surrounding the drug’s potential side effects can lead to treatment delays,” co-senior researcher Dr. Barbara Joy Snider, a professor of neurology at Washington University School of Medicine in St. Louis, said in a news release.

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients on lecanemab, including the few who may experience severe side effects,” Snider said.

For the study, researchers tracked the progress of 234 patients with very mild or mild Alzheimer’s receiving lecanemab infusions at Washington University’s Memory Diagnostic Center. These patients were treated between August 2023 and October 2024.

Of the 194 patients at risk for brain swelling or bleeding, 22% developed those side effects while receiving lecanemab, results show.

Most of these cases did not show any symptoms and were only discovered on brain scans, researchers said.

Of 11 patients who developed symptoms from brain swelling or bleeding, the effects largely resolved within a few months, researchers said. No patients died.

Ultimately, only about 4% of all the patients wound up stopping lecanemab treatment due to brain swelling or bleeding, results show.

Likewise, only 1% experienced severe side effects that required hospitalization, researchers said.

“Most patients on lecanemab tolerate the drug well,” co-senior researcher Dr. Suzanne Schindler, an associate professor of neurology at Washington University School of Medicine in St. Louis, said in a news release.

“This report may help patients and providers better understand the risks of treatment, which are lower in patients with very mild symptoms of Alzheimer’s,” Schindler added.

Sources

  • Washington University School of Medicine in St. Louis, news release, May 9, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted May 2025

Read this next

Eating Healthier Can Protect Aging Brain

MONDAY, June 2, 2025 — It’s never too late to start eating right as a means of protecting your brain health, a new study says. People who improved their healthy...

Dementia Tied To Heart, Metabolic Diseases

THURSDAY, May 29, 2025 — Heart disease, strokes and diabetes contribute to many dementia cases in the United States, but the risk is not equal everywhere, a new study...

Couch Potatoes Have Greater Risk Of Brain Decline, Even If They Exercise

MONDAY, May 19, 2025 — Couch potatoes are more likely to develop Alzheimer’s disease, even if they set aside time to work out each day, a new study says. People who...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.